Noninterventional Study - Advanced HER2-positive Breast Cancer (Metastatic or Locally Recurrent, Inoperable): First-Line Treatment With PERJETA After Adjuvant Herceptin Therapy (HELENA)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 24 Mar 2017
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms HELENA
- Sponsors Roche
- 21 Mar 2017 Planned End Date changed from 1 Sep 2017 to 15 Dec 2020.
- 21 Mar 2017 Planned primary completion date changed from 1 Sep 2017 to 15 Dec 2020.
- 01 Sep 2016 Planned End Date changed from 1 Mar 2019 to 1 Sep 2017.